CAU
MRVI icon

Caxton Associates (UK)’s Maravai LifeSciences MRVI Stock Holding History

Caxton Associates (UK)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702K Buy
+112,479
New +$486K 0.01% 478
2026
Q1 		– Sell
-150,751
Closed -$490K – 924
2025
Q4 		$490K Buy
+150,751
New +$508K 0.01% 509

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Caxton Associates (UK)'s MRVI Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 112,479 shares worth $702K. The stake represents 0.01% of the portfolio and ranks #478 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in MRVI as recently as Q4 2025.

Caxton Associates (UK) first reported a position in MRVI in Q4 2025 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Caxton Associates (UK) held 112,479 shares of Maravai LifeSciences worth $702K as of Q2 2026.
  • Maravai LifeSciences was a new Caxton Associates (UK) position in Q2 2026.
  • Maravai LifeSciences made up 0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #478 holding.
  • Caxton Associates (UK) first reported a position in Maravai LifeSciences in Q4 2025 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.